The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma.

Hui Zeng,Qi Xu,Jinyu Wang,Xiaoqing Xu,Jun Luo,Lei Zhang,Cong Luo,Jieer Ying,Jingjing Li

Frontiers in immunology（2023）

引用 5|浏览7

暂无评分

摘要

This study found that ICI+TKI and ICI+BEV as first-line treatments were similar in OS, PFS, and tumor response in uHCC. Different populations are suitable for different regimens because of the different adverse events.

查看译文

关键词

VEGF receptor tyrosine kinase inhibitors,bevacizumab,first-line treatment,hepatocellular carcinoma,immune checkpoint inhibition

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要